Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.
about
Viral hepatitis and hepatocellular carcinomaAmantadine therapy for chronic hepatitis CMeta-analysis of individual patient data from randomized trials: a review of methods used in practice.The role of the hepatitis C virus glycoproteins in infection.Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.Hepatitis C: retreatment and treatment of patients with renal failure.Treatment of chronic hepatitis C virus infection in patients with cirrhosis.Treatment of hepatitis C virus infectionPredictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis CEffects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection.Evolution of interferon-based therapy for chronic hepatitis C.Hepatitis C advances in antiviral therapy: what is accepted treatment now?Management of viral hepatitis C.Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C.Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.Effect of pegylated interferon on non-responders and relapsers with interferon.Future therapies for chronic hepatitis C.Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin.Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C.High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy.Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C.Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.What should we advise about adjunctive therapies, including herbal medicines, for hepatitis C?Viral hepatitis: Impact of adherence to combination therapy for hepatitis C.High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C.Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis.Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group.Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load.Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin.[The sustained response rates for chronic hepatitis C patients undergoing therapy with the several interferons and ribavarins supplied by Brazilians Health Ministry is comparable to those reported in the literature].Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial.Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy.Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.
P2860
Q21245597-C1C626A4-0B2A-4671-A502-51738C4E826AQ27473307-5BCAF40D-9CA0-451E-873E-B884F73E267AQ31016826-2D63F86D-76D8-4E7A-AE3F-7C83199AC4B7Q33860756-C3E6ED82-584A-4F15-AC20-28BB23E9A99DQ33947375-E5D4BB6B-A0ED-42FC-AB92-BA087E71B72FQ33988112-A76CE193-745B-477A-9EA4-9933EF1995B4Q34022678-9C9DA536-3F8F-4D89-A631-8D200FA8DCC2Q34099424-07D016ED-3B57-4BB7-A130-48D09FE98498Q34225261-ED59502C-EFC8-466D-8E5D-6A69CA1EF98BQ34294938-3F57D77B-7F3B-4B65-B95C-CF8D316A84ADQ34342092-B974F804-940F-44DF-93F9-A27279962387Q34619384-61E7E67F-BC9E-4ACF-A279-F30D317A6C49Q34631375-A1AA3670-B28A-4ADA-9EDD-5CEA66343F70Q34799396-C066CA22-5DFE-4B30-852E-6F485FEDC20DQ35073553-C2271464-4FBD-47DF-9C40-629DC1FD4DD2Q35217294-F330C57D-D0A2-477C-AACF-15B019705371Q38082566-0D5822F7-C3B3-4F32-9372-E2D978F41426Q39705689-A9D1DCE7-F805-40A7-8F6C-208886BA2ED9Q42977694-54A06926-2080-4F0F-828E-1945E0076174Q42999278-41278995-2A0D-4050-8D86-FB2522A69B4BQ43001306-B7F78743-44CC-4B0F-9A66-16E03194635AQ43034289-70170613-C5A7-4FC1-ABFA-8D081C2D7C02Q43038514-2848F694-FDCA-4BEC-85C3-A8F0DF57D5F1Q43047895-6E37B6AE-384F-4DDC-8684-43DE724C0229Q43292657-E9B70B51-095B-49A8-8C24-61B032949AADQ43505689-54490764-C802-4FB3-A8DE-4426A95E4E55Q43634174-CA42835C-A626-4E1D-AF2A-275E175DBF96Q43649889-239DBD9F-5DBF-42BD-B308-1FD29B9F0672Q44115945-C543CF83-EB27-4437-820C-D651B420646EQ45737598-51B4F197-9ECE-48B9-8824-2E12B5EE01EAQ46225118-239204C1-F45C-4B8B-A6DA-0D59A4B8FABDQ50552096-4971C29F-A914-4F3D-8750-A2B48560FF88Q50571757-15088E12-CE11-4AD7-9767-AF0168F5EC13Q50580363-1F748DFE-4F4F-4A4B-8DB3-CD6D73A26E21Q50585032-3753C546-8C92-4F46-A0A0-A443AD968055Q50586689-75FAEFBA-814A-4EAC-BA14-544A97A69CDFQ50586981-09DEA935-B7C2-4117-9326-7C5E8CE7EEF8
P2860
Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Interferon-ribavirin for chron ...... udy Group for Viral Hepatitis.
@ast
Interferon-ribavirin for chron ...... udy Group for Viral Hepatitis.
@en
type
label
Interferon-ribavirin for chron ...... udy Group for Viral Hepatitis.
@ast
Interferon-ribavirin for chron ...... udy Group for Viral Hepatitis.
@en
prefLabel
Interferon-ribavirin for chron ...... udy Group for Viral Hepatitis.
@ast
Interferon-ribavirin for chron ...... udy Group for Viral Hepatitis.
@en
P2093
P50
P1433
P1476
Interferon-ribavirin for chron ...... tudy Group for Viral Hepatitis
@en
P2093
A Bellobuono
A Hollander
J T Brouwer
L Chemello
S W Schalm
P304
P356
10.1053/GAST.1999.0029900408
P407
P577
1999-08-01T00:00:00Z